Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €23.63 EUR
Change Today -0.311 / -1.30%
Volume 0.0
G7H On Other Exchanges
Symbol
Exchange
Berlin
As of 3:45 PM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

genomic health inc (G7H) Snapshot

Open
€23.83
Previous Close
€23.94
Day High
€23.96
Day Low
€23.51
52 Week High
03/16/15 - €31.84
52 Week Low
08/8/14 - €18.56
Market Cap
762.3M
Average Volume 10 Days
2.1
EPS TTM
--
Shares Outstanding
32.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOMIC HEALTH INC (G7H)

genomic health inc (G7H) Related Businessweek News

View More BusinessWeek News

genomic health inc (G7H) Details

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.

752 Employees
Last Reported Date: 03/12/15
Founded in 2000

genomic health inc (G7H) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $660.0K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $475.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

genomic health inc (G7H) Key Developments

Genomic Health Announces Results from Multiple Studies with the Oncotype DX Tests

Genomic Health announced results from multiple studies with the Oncotype DX tests presented at the recent 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations reinforce the robustness of the Oncotype DX® tests across invasive breast cancer, ductal carcinoma in situ (DCIS) and prostate cancer, which, to date, have helped guide treatment decisions for more than half a million patients worldwide. Two DCIS studies reinforce independent value of Oncotype DX DCIS Score™ result: A secondary analysis1 from the second large validation study of the Oncotype DX test in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ) evaluated the DCIS Score™ result as a predictor of local recurrence in 718 patients treated with breast-conserving surgery (BCS) alone with any surgical margin width. The analysis showed that, in all patients regardless of margin status, the DCIS Score result was significantly associated with the 10-year risk of local recurrence (p<0.001). These results underscore the value of the DCIS Score result in providing unique tumour biology information that is not readily apparent by margin status alone. A separate secondary analysis2 evaluated the correlation between the DCIS Score result and clinicopathologic features, such as age, tumour size, nuclear grade and multifocality. The results from 571 women with DCIS who had BCS alone and clear margins showed that the DCIS Score result quantifies risk of local recurrence independent of clinicopathologic features, reconfirming findings from the previous clinical validation study.

Genomic Health Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 08:30 AM

Genomic Health Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 08:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: G. Bradley Cole, Chief Financial Officer, Chief Operating Officer, Secretary and Member of Non-Management Stock Option Committee.

Genomic Health Inc. Announces Oncotype DX® Prostate Cancer Test Improves Risk Assessment for One in Four Men and Reduces Overall Healthcare Costs

Genomic Health Inc. announced results from three studies that show the positive impact of the Oncotype DX® Genomic Prostate Score (GPS) and the test's value in managing healthcare costs associated with treatment decisions in low-risk patients. The data were presented at the 2015 American Urological Association (AUA) Annual Meeting in New Orleans. An analysis of the performance of the Oncotype DX GPS in the first 4,000 men tested showed that the test refined patient risk for one in four men across all groups of patients (25.2%).  The large shift in risk assessment was observed among NCCN® low-risk patients (48.2%). Of those patients, 36.9% had more favorable biology consistent with very-low risk, and 11.3% of patients had less favorable biology, consistent with higher-risk disease. In a separate study, researchers analyzed Oncotype DX test results from 200 U.S. prostate cancer patients to see how the change in their treatment decision based on the GPS results affected the cost of their treatment. Results showed that immediate treatment costs declined by more than $5,700 per patient. This reduction in costs was associated with increased use of active surveillance from 44% to 70% of the time. These results indicate that incorporating GPS into treatment decisions can reduce overall healthcare costs within five years. To further advance the understanding of the use of genomics in African-American men with prostate cancer, Genomic Health researchers analyzed data compiled from four different Oncotype DX prostate cancer test studies involving 138 African-American patients. Results of this analysis showed that the tumor biology measured by the Oncotype DX GPS was similar between African-American and Caucasian men, reinforcing findings from the second validation study conducted in collaboration with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research (CPDR).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
G7H:GR €23.63 EUR -0.311

G7H Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $18.62 USD +0.04
Enzo Biochem Inc $2.80 USD +0.21
Foundation Medicine Inc $35.78 USD +0.32
NanoString Technologies Inc $14.76 USD +0.70
NeoGenomics Inc $5.52 USD -0.08
View Industry Companies
 

Industry Analysis

G7H

Industry Average

Valuation G7H Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit www.genomichealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.